Autopsy report · NCT02507232

Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas

“low enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 9 months before it started.
• Ran for about 3 years 3 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

Santosh Kesari

Sponsor type

University, hospital or other

Conditions

Glioma

Interventions

NovoTTF-200A; Temozolomide

Participants

2

Sites

2

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.